



Estimation of the adherence to biological treatment in patients with psoriasis OHP-034


I. Loizaga-Diaz
1, Z. Perez-Espana
1, S. Vallinas-Hidalgo
1, A. Llona-Armada
1, F.J. Goikolea-Ugarte
1, A.V. Aguirrezabal-Arredondo
1, M.J. Yurrebaso-Ibarreche
1, Basurto University Hospital
1, Pharmacy Service
1, Pharmacy Service
1, Pharmacy Service
2, Basurto University Hospital
3, Pharmacy Service
4, Basurto University Hospital
4, Basurto University Hospital
5, Basurto University Hospital
6, Basurto University Hospital
7, Basurto University Hospital
8, Basurto University Hospital
9, Basurto University Hospital
1, Basurto University


Objectives: Quantify the adherence of patients with psoriasis to treatment with biologics (adalimumab, etanercept and infliximab)

Methods: Observational retrospective study of psoriasis patients who were prescribed biologics.

- Sex, age, type of biologic, dosage
- •adherence %adherence= no of dispensed units/ no of foreseen units x100

Results: 62 patients, 45 males/17 females, mean age of 50 years (range 12-81)





Discussion: A register of dispensations was used for calculated adherence, this is an indirect method of measure, this could mean that the adherence rate could be overestimated. As described in the literature, adherence to biologics was significantly higher compared with the adherence observed with other medications for psoriasis. Infliximab presents the major rate, maybe because it has intrahospitalary administration. There was no difference between adalimumab and etanercept.

Conclusion: The adherence we have obtained to biologics was high. It is known that exist a progressive loss of patient adherence to treatment, for this reason is important to focus the attention on this concept.

